Coronary Artery DiseaseNCT02084888
Prognostic Impact of Chronic Total Occlusions
An observational study of Coronary Artery Disease and Chronic Total Occlusions, run by Sahlgrenska University Hospital at 1 site in Sweden.
Trial summary
The purpose of this study is to determine the prognostic impact of the presence of chronic total occlusions (CTO) of the coronary arteries in patients undergoing coronary angiography and PCI. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Coronary Artery Disease, Chronic Total Occlusions
- How many people
- 91,154 participants
- Where
- 1 siteSweden
- Study dates
- Jan 2005to Jan 2012
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The study is based on all patients who underwent diagnostic coronary angiography and were registered in SCAAR during the period 2005 to January 2012 . Only patients who were diagnosed with significant coronary artery disease were included in the analyses.
Who may be able to join
- Patient with angiographic diagnosis of significant CAD registered in SCAAR between January 2005 and january 2012
Who cannot join
- Previous CABG surgery
- Missing data on coronary anatomy
- Patients who underwent a procedure for ACS in whom the 100% occlusion was located in the same coronary artery as the culprit vessel
- Patients who underwent a procedure in the same vessel within the previous 3 months
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Prognostic Impact of Chronic Total Occlusions - A Report From the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
The purpose of this study is to determine the prognostic impact of the presence of chronic total occlusions (CTO) of the coronary arteries in patients undergoing coronary angiography and PCI.
Read the detailed description
The SCAAR registry
The SCAAR registry was established in 1999 and is a part of the national SWEDEHEART registry. The registry gathers data on all consecutive patients from all hospitals that perform coronary angiography and PCI in Sweden. The information about clinical characteristics and procedural details is entered into the registry immediately after the procedure by the PCI physician after the review of clinical information. SCAAR is independent of commercial funding and is sponsored by the Swedish Health Authorities only. The technology has been developed and administered by the Uppsala Clinical Research Center, Uppsala, Sweden. Since 2001, it has a web-based case-report platform with automatic data surveillance.
Study population
The study population consisted of all consecutive patients that underwent coronary angiography or PCI in Sweden who were registered between 2005 to 2012 in Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
Definitions
The investigators defined CTO as 100% luminal diameter stenosis and the absence of antegrade flow known or assumed to be ≥3 months duration. Coronary artery disease (CAD) was defined as a luminal narrowing ≥50% on angiography. Procedural success after PCI treatment of the coronary lesion is defined as residual stenosis < 50%, decreased grade of stenosis after intervention by at least 20%, TIMI flow ≥ II and no serious complications.
Study cohort
The study was based on patients who underwent diagnostic coronary angiography and were registered in SCAAR during the period 2005 to January 2012. Only patients who were diagnosed with significant coronary artery disease were included in the analyses. A CTO patient was identified based on the available information about the percentage of luminal stenosis at the level of coronary segments that was introduced in 2005. From this date onwards, the information derived from a diagnostic coronary angiogram can also be used to determine if a coronary segment was totally occluded. In order to differentiate between acute and chronic occlusions, we excluded patients who underwent a procedure for ACS in whom the 100% occlusion was located in the same coronary artery as the culprit vessel. Furthermore, we excluded patients who underwent a procedure in the same vessel within the previous 3 months. The patients with previous coronary artery bypass graft (CABG) surgery were excluded from analysis as the patency of the graft could not be determined.
Validation
Validation of the CTO definition was performed in a subgroup of 955 patients from one university hospital (Sahlgrenska University Hospital) and from three county hospitals (Norra Älvsborgs Hospital, Borås Hospital, Skövde Hospital). This subgroup represents 5.7% of all identified CTO patients in SCAAR in the study period. The patients were randomly selected by means of random number generator. The validation procedure was conducted by a panel consisting of five experienced interventional cardiologists. The panelists examined individual coronary angiograms according to a monitoring plan defined in advance. Each angiogram was evaluated in regard to whether the patient had previous CABG, whether the treated occlusion was ≥3 months old and whether 100% segmental stenosis on angiogram was an occlusion ≥3 months old. The results from the validation procedure were then compared to the data entered in SCAAR.
Statistical analysis
Differences in baseline characteristics between the groups were tested with the χ2 test for categorical variables while Mann-Whitney U test and Kruskal-Wallis test were used for comparison of continuous non-normally distributed variables. Shapiro-Wilks test was used as a test for normal distribution. Statistical significance was defined as a P-value <0.05. The primary outcome was all-cause mortality. Unadjusted survival was examined using a Kaplan-Meier survival curve and the log-rank test. To evaluate the association between presence of CTO and mortality, multivariable-adjusted hazard ratios (HR) were calculated using Cox proportional-hazards regression models. All tests were two-sided. The potential confounders such as; age, gender, diabete, hypertension, hyperlipidemia, smoking status, previous PCI, previous MI, extent of CAD, indication, puncture site, any complication, primary treatment decision, were all entered into the model. We prespecified six subgroup analyses for the following patient categories: indication for angiography and PCI (stable angina, UA/non-STEMI, STEMI and other) severity of CAD (one-, two-, three-vessel and left main disease) age, gender, diabetes and calendar year. The possible effect modification of CTO on risk of dying in the subgroups was analyzed by means of interaction test. Age was examined in the interaction with CTO both as a continuous as well as factorial variable consisting of four different age groups namely <59, 60-69, 70-79 and >80 years. The assumption of proportional hazards for each covariate was reviewed separately by the means of log-minus-log survival plots and by formal test based on scaled Schoenfeld residuals. Possible multicollinearity between the variables in the model was assessed by calculation of variance inflation factor. The database was scrutinized for missing data. A number of variables listed above were associated with missing data. In addition to the complete case analysis, we applied multiple imputation method to estimate the missing data and performed Cox proportional hazards regression with the imputed data set under the assumption that missing data are missing at random. The imputation protocol consisted of the chain-equation method with a predictive-mean matching algorithm using the same covariates as in the main analysis with 20 imputed data sets with addition of cumulative hazard and event indicator. Cumulative hazard was estimated with the Nelson-Aalen's test. Due to hierarchical structure of SCAAR with clustering of patients within hospitals causing violation of assumption of independency between the patients, we applied multilevel modeling with shared frailty Cox proportional-hazards regression to adjust for the clustering effect. This was the primary model. The secondary model was based on complete-case analysis. All analyses were performed using Stata software (version 13.1, StataCorp, College Station, Texas, USA). The imputation procedure and subsequent Cox proportional hazards regression estimation was performed according to the Rubin's protocol.
- Conditions
- Coronary Artery Disease, Chronic Total Occlusions
- Medical subject headings
- Coronary Artery Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
All cause Mortality
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2014 (estimated)
- Study startJan 2005
- Primary completionJan 2012
- Study completionJan 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- More trials run by Sahlgrenska University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Enrolment
- 91,154 participants (actual)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Sahlgrenska University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Truls Råmunddal, Sahlgrenska University Hospital
- Investigators
- Truls Råmunddal, MD PhD, Principal investigator, Sahlgrenska University HospitalElmir Omerovic, MD PhD, Study chair, Sahlgrenska University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02084888
- Sponsor's protocol ID
- SCAAR-CTO-01
- Status last verified
- Mar 2014
- First submitted
- 10 Mar 2014
- Last updated
- 12 Mar 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Impact of Chronic Total Occlusions - A Report From the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
- ClinicalTrials.gov ID
- NCT02084888
- Acronym / sponsor ID
- SCAAR-CTO-01
- Conditions
- Coronary Artery Disease, Chronic Total Occlusions
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 91,154 participants (actual)
- Lead sponsor
- Sahlgrenska University HospitalUniversity, hospital or other
- Study start
- Jan 2005
- Primary completion
- Jan 2012 (actual)
- Study completion
- Jan 2012 (actual)
- First posted
- 12 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine the prognostic impact of the presence of chronic total occlusions (CTO) of the coronary arteries in patients undergoing coronary angiography and PCI.
Detailed description
The SCAAR registry
The SCAAR registry was established in 1999 and is a part of the national SWEDEHEART registry. The registry gathers data on all consecutive patients from all hospitals that perform coronary angiography and PCI in Sweden. The information about clinical characteristics and procedural details is entered into the registry immediately after the procedure by the PCI physician after the review of clinical information. SCAAR is independent of commercial funding and is sponsored by the Swedish Health Authorities only. The technology has been developed and administered by the Uppsala Clinical Research Center, Uppsala, Sweden. Since 2001, it has a web-based case-report platform with automatic data surveillance.
Study population
The study population consisted of all consecutive patients that underwent coronary angiography or PCI in Sweden who were registered between 2005 to 2012 in Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
Definitions
The investigators defined CTO as 100% luminal diameter stenosis and the absence of antegrade flow known or assumed to be ≥3 months duration. Coronary artery disease (CAD) was defined as a luminal narrowing ≥50% on angiography. Procedural success after PCI treatment of the coronary lesion is defined as residual stenosis < 50%, decreased grade of stenosis after intervention by at least 20%, TIMI flow ≥ II and no serious complications.
Study cohort
The study was based on patients who underwent diagnostic coronary angiography and were registered in SCAAR during the period 2005 to January 2012. Only patients who were diagnosed with significant coronary artery disease were included in the analyses. A CTO patient was identified based on the available information about the percentage of luminal stenosis at the level of coronary segments that was introduced in 2005. From this date onwards, the information derived from a diagnostic coronary angiogram can also be used to determine if a coronary segment was totally occluded. In order to differentiate between acute and chronic occlusions, we excluded patients who underwent a procedure for ACS in whom the 100% occlusion was located in the same coronary artery as the culprit vessel. Furthermore, we excluded patients who underwent a procedure in the same vessel within the previous 3 months. The patients with previous coronary artery bypass graft (CABG) surgery were excluded from analysis as the patency of the graft could not be determined.
Validation
Validation of the CTO definition was performed in a subgroup of 955 patients from one university hospital (Sahlgrenska University Hospital) and from three county hospitals (Norra Älvsborgs Hospital, Borås Hospital, Skövde Hospital). This subgroup represents 5.7% of all identified CTO patients in SCAAR in the study period. The patients were randomly selected by means of random number generator. The validation procedure was conducted by a panel consisting of five experienced interventional cardiologists. The panelists examined individual coronary angiograms according to a monitoring plan defined in advance. Each angiogram was evaluated in regard to whether the patient had previous CABG, whether the treated occlusion was ≥3 months old and whether 100% segmental stenosis on angiogram was an occlusion ≥3 months old. The results from the validation procedure were then compared to the data entered in SCAAR.
Statistical analysis
Differences in baseline characteristics between the groups were tested with the χ2 test for categorical variables while Mann-Whitney U test and Kruskal-Wallis test were used for comparison of continuous non-normally distributed variables. Shapiro-Wilks test was used as a test for normal distribution. Statistical significance was defined as a P-value <0.05. The primary outcome was all-cause mortality. Unadjusted survival was examined using a Kaplan-Meier survival curve and the log-rank test. To evaluate the association between presence of CTO and mortality, multivariable-adjusted hazard ratios (HR) were calculated using Cox proportional-hazards regression models. All tests were two-sided. The potential confounders such as; age, gender, diabete, hypertension, hyperlipidemia, smoking status, previous PCI, previous MI, extent of CAD, indication, puncture site, any complication, primary treatment decision, were all entered into the model. We prespecified six subgroup analyses for the following patient categories: indication for angiography and PCI (stable angina, UA/non-STEMI, STEMI and other) severity of CAD (one-, two-, three-vessel and left main disease) age, gender, diabetes and calendar year. The possible effect modification of CTO on risk of dying in the subgroups was analyzed by means of interaction test. Age was examined in the interaction with CTO both as a continuous as well as factorial variable consisting of four different age groups namely <59, 60-69, 70-79 and >80 years. The assumption of proportional hazards for each covariate was reviewed separately by the means of log-minus-log survival plots and by formal test based on scaled Schoenfeld residuals. Possible multicollinearity between the variables in the model was assessed by calculation of variance inflation factor. The database was scrutinized for missing data. A number of variables listed above were associated with missing data. In addition to the complete case analysis, we applied multiple imputation method to estimate the missing data and performed Cox proportional hazards regression with the imputed data set under the assumption that missing data are missing at random. The imputation protocol consisted of the chain-equation method with a predictive-mean matching algorithm using the same covariates as in the main analysis with 20 imputed data sets with addition of cumulative hazard and event indicator. Cumulative hazard was estimated with the Nelson-Aalen's test. Due to hierarchical structure of SCAAR with clustering of patients within hospitals causing violation of assumption of independency between the patients, we applied multilevel modeling with shared frailty Cox proportional-hazards regression to adjust for the clustering effect. This was the primary model. The secondary model was based on complete-case analysis. All analyses were performed using Stata software (version 13.1, StataCorp, College Station, Texas, USA). The imputation procedure and subsequent Cox proportional hazards regression estimation was performed according to the Rubin's protocol.
Study design
- Observational model
- Cohort
- Target follow-up
- 3 Years
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The study is based on all patients who underwent diagnostic coronary angiography and were registered in SCAAR during the period 2005 to January 2012 . Only patients who were diagnosed with significant coronary artery disease were included in the analyses.
Key inclusion criteria (1 listed)
- Patient with angiographic diagnosis of significant CAD registered in SCAAR between January 2005 and january 2012
Key exclusion criteria (4 listed)
- Previous CABG surgery
- Missing data on coronary anatomy
- Patients who underwent a procedure for ACS in whom the 100% occlusion was located in the same coronary artery as the culprit vessel
- Patients who underwent a procedure in the same vessel within the previous 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
All cause Mortality
Time frame: 3 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2014.
Related trials for Coronary Artery Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingObservational study
Preoperative Gastric Ultrasound and Left Ventricular Function in Coronary Artery Bypass Surgery
Coronary Artery Disease, Left Ventricular Systolic Dysfunction
Active, not recruiting
The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)
Ischaemic Heart Disease, Ischemic Heart Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Truls Råmunddal, MD PhD principal investigator
Sahlgrenska University Hospital
Elmir Omerovic, MD PhD study chair
Sahlgrenska University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease and Chronic Total Occlusions, run by Sahlgrenska University Hospital at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Mar 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
All cause Mortality (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2014.